Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients With Dry Eye After LASIK

ConditionDry Eye
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-40
SponsorHe Eye Hospital

About this trial

The prevalence of refractive ametropia is rising year by year. Refractive surgery has become the main approach for adults to correct refractive ametropia, and postoperative complications have aroused extensive attention from clinicians. Dry eye after refractive surgery is one of the postoperative complications, which is an important cause of affecting the postoperative visual quality and satisfaction of patients. It was reported that 3% diquafosol (DQS) and 0.1% hyaluronic acid (HA) can relieve dry eye symptoms. This study aims to compare the efficacy of 3% DQS and 0.1% HA in treating dry eye after LASIK

Eligibility criteria

Qualifiers

History of LASIK surgery for more than six months

Confirmed dry eye: patients complained of one of the subjective symptoms of ocular dryness, foreign body sensation, burning sensation, fatigue, discomfort, redness of the eyes, and fluctuating visual acuity; as well as (a) OSDI questionnaire score of ≥13 and (b) non-invasive tear break-up time (NITBUT) of <10 s or (c) ocular surface staining assessed in >5 corneal patches/greater than 9 conjunctival patches

Participants were able to co-operate with the use of eye drops as required, complete the examination, and return to the hospital within the specified time for follow-up examinations to complete the follow-up visit.

Disqualifiers

Suspected of having keratoconus, a definite diagnosis of keratoconus or another type of corneal dilatation disease.

There is active inflammation or symptoms of infection in the eye

There are serious lesions in the accessory structures of the eye, such as defects or deformations of the eyelids

Patients with Connective tissue diseases and Autoimmune disorders (e.g., SLE, RA)

Trial design

Treatments tested in this trial

  • 3% Diquafosol Sodium Eye Drops
  • 0.1% hyaluronic acid

Treatment groups

140 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators